Provided by Tiger Fintech (Singapore) Pte. Ltd.

Solid Biosciences

3.12
-0.2900-8.52%
Post-market: 3.07-0.0490-1.57%19:36 EDT
Volume:1.61M
Turnover:5.11M
Market Cap:241.39M
PE:-1.02
High:3.40
Open:3.34
Low:3.06
Close:3.41
Loading ...

Solid Biosciences Gets Fast Track Designation for Potential Friedreich's Ataxia Treatment

MT Newswires Live
·
22 Jan

Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation

Dow Jones
·
21 Jan

Solid Biosciences receives FDA Fast Track Designation for SGT-212

TIPRANKS
·
21 Jan

Solid Biosciences Receives FDA Fast Track Designation for Sgt-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

THOMSON REUTERS
·
21 Jan

Solid Biosciences Inc - Sgt-212 Dosing Expected to Initiate in Second Half of 2025

THOMSON REUTERS
·
21 Jan

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

GlobeNewswire
·
21 Jan

Solid Biosciences: Promising Advancements and Strategic Initiatives Drive Buy Rating

TIPRANKS
·
17 Jan

Solid Biosciences Outlines Key Priorities at Healthcare Conference

MT Newswires Live
·
16 Jan

BRIEF-Solid Biosciences Outlines Key Priorities For Advancing Diversified Neuromuscular And Cardiac Development Pipeline

Reuters
·
16 Jan

Solid Biosciences Inc - Cash and Investments Expected to Fund Key Strategic Priorities Into 2026

THOMSON REUTERS
·
16 Jan

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

THOMSON REUTERS
·
16 Jan

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

GlobeNewswire
·
16 Jan

Promising Developments and Strategic Advancements Support Buy Rating for Solid Biosciences

TIPRANKS
·
13 Jan

Solid Biosciences Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Jan

Solid Biosciences’ Innovative Gene Therapy SGT-212 Gains Buy Rating Amid Promising Preclinical Results and FDA Approval

TIPRANKS
·
10 Jan

Solid Biosciences (SLDB) Receives a Buy from Piper Sandler

TIPRANKS
·
10 Jan

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)

TIPRANKS
·
09 Jan

SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia

Zacks
·
08 Jan

Solid Biosciences Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $16

THOMSON REUTERS
·
08 Jan

Solid Biosciences Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $16

THOMSON REUTERS
·
08 Jan